ADMA Biologics Inc $ADMA Shares Sold by Ausbil Investment Management Ltd

Key Points

• Ausbil Investment Management Ltd reduced its stake in ADMA Biologics by 24.7%, selling 26,376 shares and now owning 80,493 shares valued at $1,466,000.
• In the first quarter, other institutional investors showed significant interest, with Intech Investment Management LLC increasing its stake by 164.2% to 292,595 shares.
• ADMA Biologics reported a quarterly earnings per share of $0.15, exceeding estimates, along with a 13.8% year-over-year revenue increase to $121.98 million.

Ausbil Investment Management Ltd reduced its stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 24.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 80,493 shares of the biotechnology company's stock after selling 26,376 shares during the period. Ausbil Investment Management Ltd's holdings in ADMA Biologics were worth $1,466,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Intech Investment Management LLC grew its stake in shares of ADMA Biologics by 164.2% in the first quarter. Intech Investment Management LLC now owns 292,595 shares of the biotechnology company's stock valued at $5,805,000 after buying an additional 181,839 shares in the last quarter. New York State Teachers Retirement System boosted its holdings in ADMA Biologics by 96.2% in the 1st quarter. New York State Teachers Retirement System now owns 221,890 shares of the biotechnology company's stock worth $4,402,000 after acquiring an additional 108,800 shares during the period. Strs Ohio acquired a new stake in ADMA Biologics in the first quarter valued at approximately $1,307,000. Vident Advisory LLC acquired a new stake in ADMA Biologics in the first quarter valued at approximately $2,735,000. Finally, Caxton Associates LLP purchased a new stake in shares of ADMA Biologics during the first quarter valued at approximately $668,000. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Trading Up 1.9%

NASDAQ ADMA opened at $15.61 on Friday. The stock has a market cap of $3.73 billion, a P/E ratio of 18.15 and a beta of 0.54. The company's fifty day simple moving average is $17.02 and its 200-day simple moving average is $18.88. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. ADMA Biologics Inc has a 52 week low of $13.50 and a 52 week high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm had revenue of $121.98 million for the quarter, compared to the consensus estimate of $121.77 million. During the same quarter in the previous year, the firm posted $0.13 EPS. The firm's quarterly revenue was up 13.8% on a year-over-year basis. Equities research analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.